Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BEIJER REF Q2 2021

Strong second quarter   Second quarter Net sales increased by 36.6% in the second quarter compared to the same period last year and amounted to SEK 4,561 million (3,338). Organic growth was strong at 33.8%. Acquisition effects amounted to 6.4%, which is offset by currency effects amounting to -3.5%. EBITA amounted to SEK 431 million (253), corresponding to an EBITA margin of 9.4% (7.6%). The operating profit amounted to SEK 418 million (241), an increase of 73.5% compared with the previous year. The operating margin amounted to 9.2% (7.2%). Profit before tax was SEK 402

SSAB has launched an extensive research project in Finland to replace fossil fuels with renewable energy in steelmaking

SSAB has launched an extensive research project, FFS – Towards Fossil-free Steel, in Finland. In the project, SSAB will work together with industrial and research partners to explore different solutions and alternatives to produce fossil-free steel and thus the ways to withdraw entirely from the use fossil energy. SSAB Raahe siteSSAB aims to be completely fossil free and to remove the company’s fossil carbon dioxide emissions by 2045. In 2016, SSAB, LKAB and Vattenfall announced the HYBRIT initiative, where the blast furnace process, which causes around 90% of the carbon dioxide

BioStock: Cyxone is exploring new treatment possibilities for T20K

After identifying new therapeutic treatment possibilities for T20K, Cyxone has announced a research collaboration with the Medical University of Vienna to further validate these findings and to deepen the understanding of T20K’s mode of action. The aim of the project is to prepare for a clinical phase I study with the new administration form. BioStock reached out to COO Carl-Magnus Högerkorp and Non-Clinical Project Manager Sally Abdelmoaty for a comment.Read the full interview at biostock.se: https://www.biostock.se/en/cyxone-is-exploring-new-treatment-possibilities-for-t20k/ This is

Calliditas secures $75 million term loan facility

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the company has signed a loan agreement of up to the Euro equivalent of $75 million with Kreos Capital. Proceeds from the loan will be utilized for the launch of Calliditas’ lead product candidate Nefecon, if approved, as well as to support clinical development efforts and for general corporate purposes.The loan facility is divided into three tranches of $25 million each. Drawdown of the first $25 million tranche can be made until 31 December 2021 and will be available after the

Ayima Newsletter - July 2021

Hello and welcome to the first of a new generation of Ayima’s newsletter – Newsletter 2.0. We hope to make this a regular quarterly publication that will bring news of the company and the Industry to our investors, clients, staff and other interested industry people. We aim to give some insight into the amazing people at Ayima and the unique culture and working environment we have built over the years. This initial edition has an update on general post-pandemic working life at Ayima from our UK Managing Director, Nicky Applegarth as well as news of an exciting new department that will

New Business Update - Ayima Group AB

Further to the New Business Update of 2 July, 2021, Ayima is pleased to announce that further new business has been signed to the value of 2.8 MSEK. This brings the total so far in Q3 to 10.9 MSEK. The new clients include a startup community website, based out of Vancouver and a famous health charity based in London. All of the new contracts signed are for SEO consulting services on Ayima's standard 12-month agreements. Ayima's CEO Mike Jacobson commented "We are continuing to see strong demand for SEO services in North America in particular, but also some signs that the market in the

Vitec Software Group AB Interim report January - June 2021

Summary of interim period, January–June 2021 · Net sales SEK 769 million (630), an increase of 22% · Recurring revenues SEK 639 million (519), an increase of 23% including 8% organic · EBITA was SEK 218 million (161), with an EBITA margin of 28% (26) · Operating profit was SEK 142 million (97), with an operating margin of 18% (15) · Earnings per share before dilution SEK 3.06 (2.19) · Cash flow from operating activities SEK 340 million (302) Summary of interim period, April–June 2021 · Net sales SEK 396 million (321), an increase of 24% · Recurring revenues

BONESUPPORT Holding AB (publ) – Publishes Q2 2021 Interim report

Lund, Sweden, 08:00 CEST, July 15, 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2021. 58% SALES GROWTH IN CONSTANT CURRENCY   APRIL – JUNE 2021 ·Net sales increased by 43 percent (58 percent at constant exchange rates) and amounted to SEK 51.8 million (36.2). · The North America (NA) segment reported a sales increase of 35 percent (56 percent at constant exchange rate). · The Europe & Rest of the World (EUROW) segment reported a sales increase

Interim report Byggmax Group AB January 1 - June 30 2021

Record result and stronger positionSUMMARY OF THE SECOND QUARTER OF 2021• Net sales increased to SEK 2,833 M (2,499), representing a growth of 13.4 percent. Exchange rate effects had apositive impact on net sales of 0.7 percent.• The Group’s currency adjusted like-for-like sales increased by 8.6 percent.• The gross margin was 33.2 percent (31.1).• EBITA amounted to SEK 456 M (357), with an EBITA margin of 16.1 percent (14.3).• EBIT amounted to SEK 446 M (347), with an EBIT margin of 15.8 percent (13.9).• Net profit for the period amounted to SEK 348 M (268).• Earnings per

Strong half-year and increased pace of investment

· Income for the period January–June 2021 totalled MSEK 2,936 (2,999). · Income from property management amounted to MSEK 1,615 (1,689), equivalent to SEK 5.88 (6.18) per share – a decrease of 5%. · Changes in value on properties amounted to MSEK 3,122 (418) and on derivatives to MSEK 117 (–209). · Net income for the period amounted to MSEK 5,550 (1,534), corresponding to SEK 20.20 (5.62) per share. · Long-term net reinstatement value (EPRA NRV) amounted to SEK 227 per share (199), an increase of 14%. · Net investments amounted to MSEK –8,986 (1,378) of which MSEK 335 (292)

DDM Holding AG and DDM Debt AB to report second quarter and half year 2021

DDM Holding AG (First North Growth Market: DDM) and its subsidiary DDM Debt AB (Nasdaq Stockholm: DDM2) will publish their Q2 and half year 2021 reports on Thursday 29 July 2021 at 08:00 CEST.Mr. Henrik Wennerholm, CEO, and Mr. Fredrik Olsson, CFO, will host a conference call the same day, beginning at 10:00 CEST, to present and comment on the DDM Group’s financial results. The conference will be held in English and can be followed live on www.ddm-group.ch  or by telephone with dial-in numbers: Sweden: +46 8 505 583 50 Switzerland: +41 225

DDM Holding AG and DDM Debt AB to report second quarter and half year 2021

DDM Holding AG (First North Growth Market: DDM) and its subsidiary DDM Debt AB (Nasdaq Stockholm: DDM2) will publish their Q2 and half year 2021 reports on Thursday 29 July 2021 at 08:00 CEST.Mr. Henrik Wennerholm, CEO, and Mr. Fredrik Olsson, CFO, will host a conference call the same day, beginning at 10:00 CEST, to present and comment on the DDM Group’s financial results. The conference will be held in English and can be followed live on www.ddm-group.ch  or by telephone with dial-in numbers: Sweden: +46 8 505 583 50 Switzerland: +41 225

AQ Group AB (publ), interim report January - June, 2021

Second quarter, April-June 2021 in brief · Strong demand and high capacity utilization in combination with continued cost control · Net sales increased by 21.9% to SEK 1,361 million (1,116) · Operating profit (EBIT) increased by 46.0% to SEK 118 million (81) · Profit after financial items (EBT) increased by 45.9% to SEK 114 million (78) · Profit margin before tax (EBT %) was 8.4% (7.0) · Cash flow from operating activities decreased by 32.0% to SEK 84 million (166) · Earnings per share after tax increased by 37.4% to SEK 5.22 (3.80) Six months, January-June 2021 in

Finnair targets c. 200-million-euro permanent cost base reduction by 2022 onwards, based on 2019 operational volumes, superseding the previously announced target

Finnair Plc         Stock Exchange Release           15 July 2021 at 9.00 a.m. EEST On 20 May 2020, Finnair announced that it was targeting nearly 80 million euros in permanent cost base reductions by 2022, compared to 2019 levels. The company updated the same target in its announcement on 25 August 2020 by increasing it to c. 100 million euros, updated it again on 28 October 2020 to c. 140 million euros and on 27 April 2021 to c. 170 million euros. Finnair has made good progress in the cost savings programme and will reach this target ahead of the schedule.  At the same time, it has

Finnair Group Half-year Report 1 January – 30 June 2021

Finnair Plc             Half-year Report            15 July 2021 at 9.00 a.m. EEST Cost adjustment and financing measures continued while Finnair was preparing for a traffic restart. As travel restrictions are reduced, demand is expected to increase gradually during the fall. April – June 2021 · Earnings per share were -0.09 euros (-0.25)*. · Revenue increased by 63.0% to 111.8 million euros (68.6). · Comparable operating result was -151.3 million euros (-174.3). Operating result was -139.1 million euros (-171.2). · Cash funds were 834.3 million euros (31 Dec 2020: 823.7)

Interim report for Q2 2021

Major progress in the licensing business and several new partnerships for wound care Second quarter (April-June 2021) · Revenues amounted to SEK 46.0 (48.2) million, a decrease of 5%. Adjusted for currencies revenues increased 5%.  · EBITDA amounted to SEK 1.8 (10.5) million with an EBITDA margin of 4% (22%).  · Operating profit amounted to SEK -10.0 (-0.8) million.  · Net loss for the period amounted to SEK -12.0 (-0.3) million. Earnings per share amounted to SEK -0.36 (-0.01).  · Cash flow from operating activities amounted to SEK 5.5 (3.6) million,

Interim Report - 6 months 1 January-30 June 2021

SECOND QUARTER (1 April-30 June 2021) · Revenue increased by 12 percent to MSEK 2,560 (2,288). · EBITA increased by 38 percent to MSEK 214 (155), corresponding to an EBITA marginof 8.4 percent (6.8). · Operating profit amounted to MSEK 194 (134) and the operating margin to 7.6 percent (5.9). · Net profit for the quarter increased by 54 percent to MSEK 145 (94) and earnings per shareto SEK 2.85 (1.85). · Demand and the earnings trend in both of the Group’s business areas continued to recover during the quarter compared both with the preceding quarter and with the

Mycronic’s Board of Directors resolves to acquire the company’s own shares

Mycronic’s Board of Directors has resolved to utilize the authorization given by the Annual General Meeting 2021 to acquire the company’s own shares in accordance with the following: 1. Acquisition may not exceed 89,600 shares in the company 2. Acquisition of shares in the company may only be made on Nasdaq Stockholm 3. Acquisition of shares on Nasdaq Stockholm may only take place at a price within the price range recorded on the Nasdaq Stockholm at any given time 4. The payment for the shares shall be made in cash 5. The resolution may be used on one or several

Invitation to the presentation of Resurs Holding’s second quarter report 2021

Resurs’s report for the second quarter 2021 will be published at 07:30 CET on July 22[nd]. A web-cast telephone conference will be held at 09:00 CET the same day, where Resurs’s CEO Nils Carlsson and CFO & Head of IR Sofie Tarring Lindell will present the report. The presentation will be followed by a Q&A session.The presentation will be held in Swedish and can be followed on the web or over the phone. The presentation will also be translated into English and can be followed on the web or over the phone. To participate in the conference call, call one of the following numbers: Sweden:

Interim report January – June 2021: Good growth and acquisition of Igenomix

Second quarter · Sales amounted to SEK 382 (209) million, corresponding to an increase of 83 percent in SEK. Sales increased by 94 percent in local currency. · Operating income before depreciation and amortisation (EBITDA) amounted to SEK 134 (40) million, corresponding to a margin of 35 (19) percent. Currency effects negatively impacted EBITDA by SEK 15 million. Operating income included non-recurring acquisition-related costs of SEK 11 million and non-recurring transport-related costs of SEK 3 million. Adjusted for these items, EBITDA amounted to SEK 148 million corresponding to a

Hansa Biopharma interim report Jan-June 2021

Idefirix[®] recommended by Swedish New Therapies Council for use in highly sensitized kidney patients in Sweden. U.S. trial design announced; first patient expected to be dosed H2 2021Lund, Sweden July 15, 2021 Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January – June, 2021. Highlights for the second quarter 2021 · Commercial launch activities for Idefirix[®] in Europe are progressing as planned in early launch countries, such as the Nordics, Benelux, U.K. and Germany.

Interim Report January-June 2021

Second quarter · Order intake amounted to SEK 1,002 (651) million, up 54 percent · Net sales decreased 2 percent to SEK 1,064 (1,086) million. Based on constant exchange rates, net sales increased6 percent · EBIT declined to SEK 241 (281) million and EBIT margin was 23 (26) percent  · Earnings per share were SEK 1.84 (2.18) January-June · Order intake amounted to SEK 2,030 (2,083) million, down 3 percent · Net sales increased 29 percent to SEK 2,355 (1,822) million. Based on constant exchange rates, the increase was39 percent · EBIT rose to SEK 739 (336)

Orexo Q2 2021 Interim Report

"First commercial DTx contract signed with a large healthcare provider"Summary · Total net revenues of SEK 142.8 m (179.1) · Net earnings of SEK -73.7 m (-32.5) · EBITDA of SEK -41.1 m (-9.0) · US Pharma segment (ZUBSOLV® US) net revenues of SEK 126.0 m (172.5), in local currency USD 15.0 m (17.8), EBIT of SEK 61.6 m (88.8) · Cash flow from operating activities of SEK -20.9 m (-7.2), cash balance of SEK 679.7 m (677.2) · Two patents for ZUBSOLV®, with protection until 2032, were issued by the US Patent and Trademark Office · First patient enrolled in pivotal study

There are no items matching the current filter
There are no more items matching the current filter
Back to top